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7RESEARCH Open AccessGuidance of treatment decisions in risk-adapted
primary radiotherapy for prostate cancer using
multiparametric magnetic resonance imaging: a
single center experience
Cedric Panje1, Thierry Panje1, Paul Martin Putora1, Suk-kyum Kim2, Sarah Haile3, Daniel M Aebersold4
and Ludwig Plasswilm1*Abstract
Background: Magnetic resonance imaging (MRI) of the prostate is considered to be the most precise noninvasive
staging modality for localized prostate cancer. Multiparametric MRI (mpMRI) dynamic sequences have recently been
shown to further increase the accuracy of staging relative to morphological imaging alone. Correct radiological
staging, particularly the detection of extraprostatic disease extension, is of paramount importance for target
volume definition and dose prescription in highly-conformal curative radiotherapy (RT); in addition, it may affect
the risk-adapted duration of additional antihormonal therapy. The purpose of our study was to analyze the
impact of mpMRI-based tumor staging in patients undergoing primary RT for prostate cancer.
Methods: A total of 122 patients admitted for primary RT for prostate cancer were retrospectively analyzed
regarding initial clinical and computed tomography-based staging in comparison with mpMRI staging. Both
tumor stage shifts and overall risk group shifts, including prostate-specific antigen (PSA) level and the Gleason
score, were assessed. Potential risk factors for upstaging were tested in a multivariate analysis. Finally, the impact
of mpMRI-based staging shift on prostate RT and antihormonal therapy was evaluated.
Results: Overall, tumor stage shift occurred in 55.7% of patients after mpMRI. Upstaging was most prominent in
patients showing high-risk serum PSA levels (73%), but was also substantial in patients presenting with low-risk
PSA levels (50%) and low-risk Gleason scores (45.2%). Risk group changes occurred in 28.7% of the patients with
consequent treatment adaptations regarding target volume delineation and duration of androgen deprivation
therapy. High PSA levels were found to be a significant risk factor for tumor upstaging and newly diagnosed
seminal vesicle infiltration assessed using mpMRI.
Conclusions: Our findings suggest that mpMRI of the prostate leads to substantial tumor upstaging, and can
considerably affect treatment decisions in all patient groups undergoing risk-adapted curative RT for prostate cancer.
Keywords: MRI, Multiparametric, Prostate cancer, RadiotherapyBackground
External beam radiotherapy (RT) of the prostate has
been established as an effective therapeutic option for
localized prostate cancer as a single treatment modality
or in conjunction with systemic androgen deprivation
therapy (ADT); it has achieved excellent rates of* Correspondence: ludwig.plasswilm@kssg.ch
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unless otherwise stated.locoregional and biochemical control [1-3]. Recent phase
III studies have demonstrated an additional improve-
ment in oncological outcome for patients presenting
with adverse risk factors including advanced T-stage,
markedly elevated serum prostate-specific antigen (PSA)
and high-grade disease by means of treatment intensifi-
cation such as radiation dose escalation and the addition
of ADT [4-6]. Current consensus guidelines recommend
extension of the target volume beyond the prostatichis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Risk group classification for localized prostate
cancer according to the National Comprehensive Cancer
Network guidelines
T Stage PSA (ng/ml) Gleason score
(Very) low risk T1–T2a < 10 2–6
Intermediate risk T2b-c 10–20 7
(Very) high risk T3a-b >20 8–10
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count for extracapsular extension (ECE) and seminal
vesicle invasion (SVI) [7]. Such an accurate target vol-
ume definition is particularly important when highly
conformal techniques such as image-guided intensity-
modulated radiotherapy (IMRT) are used [8]. However,
as a definite pathological specimen is not available like
after radical prostatectomy, curative RT for prostate can-
cer relies primarily on accurate clinical and radiological
tumor staging for risk group-adapted treatment intensifi-
cation as well as for target volume delineation [7,9].
To date, magnetic resonance imaging (MRI) of the
prostate is considered to be the most accurate imaging
modality available for the noninvasive determination of
the local extent of prostate cancer [10,11]. More recently,
prostate morphological imaging involving T1- and T2-
weighted MRI has been routinely complemented by multi-
parametric dynamic sequences such as diffusion-weighted
imaging (DWI) and dynamic contrast-enhanced imaging,
which have been shown to further increase specificity and
sensitivity [12-14]. MRI of prostate cancer allows for the
reliable detection of adverse pathological features such as
ECE and SVI [15-18]. It has also shown a superior congru-
ence with the final surgical-pathological staging relative to
digital rectal examination, transrectal ultrasound-guided
biopsy and computed tomography (CT) [19,20], as well as
compared with prediction tools such as the Partin tables
[21,22] and the Kattan nomogram [23].
A small number of previous studies have demon-
strated that morphological MRIs of localized prostate
cancer resulted in a significant tumor stage shift with
consequent implications regarding target volume defin-
ition [24] and more accurate prediction of treatment
outcome [25]. However, to our knowledge, the impact of
state-of-the-art multiparametric MRI (mpMRI) of the
prostate on curative RT for prostate cancer and add-
itional ADT has not yet been specifically investigated.
Consequently, the purpose of our study was to retro-
spectively analyze the value of mpMRI for prostate can-
cer staging before curative RT and its impact on
treatment decisions.
Methods
Patient selection
After review and the approval of the institutional ethics
committee (Ethics Committee St. Gallen, Switzerland),
160 patients with clinically localized prostate cancer
were identified. These patients had been referred to the
Cantonal Hospital St. Gallen between January 2010 and
December 2013 for primary RT, based on patient prefer-
ence or medical inoperability; they had all received a
mpMRI of the prostate before RT. For further analysis
patients who met the following staging criteria before
undergoing a pelvic MRI scan (n = 122) were included:histopathological confirmation of prostate cancer using
transrectal ultrasound-guided biopsy evaluated accord-
ing to the Gleason grading system [26]; a complete med-
ical history and physical examination; a serum PSA
measurement; and a CT scan of the abdomen and pelvis.
Clinical stage before the MRI scan was determined using
the 2010 International Union Against Cancer (UICC),
7th edition staging criteria [27].
Based on the pre-treatment serum PSA, histopatho-
logical Gleason Score and clinical staging patients were
assigned to low-risk, intermediate-risk and high-risk
groups according to the 2014 National Comprehensive
Cancer Network (NCCN) guidelines on prostate can-
cer (Table 1) [28].
mpMRI protocol
mpMRI of the prostate was typically performed on the
same day as the planning CT at 1 week prior to the be-
ginning of RT. MRI examinations were performed using
a 3 Tesla (38%) or 1.5 Tesla MRI (59%) scanner (Verio,
Avanto and Symphony: Siemens Healthcare, Forchheim,
Germany), and the signals were acquired using a 32-
channel-phased-array-bodycoil (Siemens Healthcare,
Forchheim, Germany). Morphological imaging included
T2-weighted turbo spin-echo (TSE) sequences in axial
and sagittal planes, as well as precontrast T1-weighted
TSE sequences in coronal planes covering the prostate
and the seminal vesicles. DWIs were acquired using
single-shot spin-echo-echo planar imaging with differ-
ent b-values. Dynamic contrast-enhanced MRI (DCE-
MRI) was acquired using 3D T1-weighted spoiled
gradient echo sequence and contrast agent was injected
using a motorized power injector. The DCE-MRI data-
sets were transferred to a dedicated radiological work-
station (Multimodality Workplace: Siemens Healthcare,
Forchheim, Germany) and analyzed by a board-certified
radiologist. Three patients (2.5%) underwent an equiva-
lent MRI study in other institutions prior to RT.
Risk-adapted institutional treatment stratification and
target volume definition
Planning CT and mpMRI were usually scheduled on the
same day to allow for image fusion and improved MR-
based target volume delineation [29,30]. Target volume
definition was performed according to current guidelines
Table 2 Patient characteristics (n = 122)
Patient parameter Value
Median age (years; range) 71.5 (50.9–83.3)
Gleason score, n (%)
Low risk (2–6) 50 (41%)
Intermediate risk (7) 48 (39.3%)
High risk (8–10) 23 (18.9%)
Serum PSA (ng/ml), n (%)
Low risk (<10) 52 (42.6%)
Intermediate risk (10–20) 38 (31.1%)
High risk (>20) 32 (26.2%)
Initial tumor stage (clinical examination and CT), n (%)
Low risk (T1–2a) 53 (43.4%)
Intermediate risk (T2b-c) 44 (36.1%)
High risk: extracapsular extension (T3a) 21 (17.2%)
High risk: seminal vesicle infiltration (T3b) 4 (3.3%)
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in the clinical target volume (CTV). In the intermediate-
risk and high-risk groups the CTV was extended with a
radial margin of up to 5 mm around the prostatic cap-
sule including the base of the seminal vesicles to account
for the increased risk of microscopic ECE. In the case of
macroscopic ECE diagnosed on MRI, an additional mar-
gin around the extracapsular spread was chosen. Seminal
vesicles were included in the CTV when tumor invasion
was clinically or radiologically suspected.
RT was planned depending on the risk group. A total
dose of 72–76 Gy (2 Gy per fraction, 5 fractions per
week) using 3D-conformal RT or dynamic IMRT tech-
niques was delivered. Patients were instructed in the use
of a specific bladder and rectum filling protocol to
minimize interfraction internal movement of the pelvic
organs. ADT was prescribed in the absence of contrain-
dications according to current evidence for 4–6 months
for intermediate-risk patients and for 2–3 years for high-
risk patients [6,28,31-33]. No ADT was given in the case
of low-risk patients.
Analysis of potential risk factors predicting tumor
upstaging and seminal vesicle infiltration using mpMRI
To identify risk factors which increased the probability
of tumor upstaging and the detection of seminal vesicle
involvement using mpMRI, the following patient char-
acteristics were investigated in univariate and multi-
variate analyses: age; the Gleason score; serum PSA
level; initiation of ADT before MRI; and in the case of
seminal vesicle involvement, initial tumor stage. For
the analysis, the Gleason score, PSA level and tumor
stage were assigned to the low-risk, intermediate-risk
and high-risk groups using the cut-off values men-
tioned above [28].
Statistical methods
Agreement between ratings using CT and MRI was
summarized using Cohen’s weighted kappa coefficient
(with squared weights) and the corresponding 95%
bootstrapped confidence interval (CI), or as the per-
centage agreement with the corresponding 95%
(Wilson) CI. Logistic regression was used to examine
the association between age, PSA level, the Gleason
score, tumor stage and anti-hormonal therapy with the
probability of upstaging (MRI versus clinical staging).
A significance level of 0.05 was used throughout. All
analyses were performed in the R programming language
(version 3.1.0) [34].
Results
Patient characteristics
Patient characteristics are summarized in Table 2. The
median age of the 122 study patients was 71.5 +/− 5.9 yearswith a range of 50.9 to 83.3 years. 42.6% of the pa-
tients (n = 52) had a pre-treatment serum PSA level
of < 10 ng/ml, 31.1% (n = 38) a PSA level of 10–20 ng/ml,
26.2% (n = 32) presented with a PSA level of > 20 ng/ml.
After histopathological grading using ultrasound-
guided transrectal biopsy 41% (n = 50) of the patients
had a Gleason score of < = 6, 39.3% (n = 48) had a
Gleason score of 7 and 18.9% (n = 23) had a Gleason
score of 8–10. The Gleason score was not assessable
in one patient.
ADT had been initiated before the MRI scan in 46.7%
of the patients (n = 57). The median duration of ADT
before RT was 51.5 days with a duration of > 6 months
in only 3.8% of the patients who had received both
ADT and RT (n = 2).
Based on clinical staging before the MRI scan, the
UICC clinical stage for prostate cancer was T1c-T2a in
43.4% patients (n = 53), T2b-c in 36.1% of the patients
(n = 44) and T3a in 17.2% (n = 21). Seminal vesicle infil-
tration (T3b) was suspected in 3.3% (n = 4). Addition-
ally, 3.3% of the patients had suspected nodal
involvement on the CT scan. According to the criteria
of the NCCN 2014 guidelines [28], each T-stage was
assigned to the corresponding risk group for further
analysis; this resulted in 43.4% of tumors being classi-
fied as being in the low-risk group (T1-2a), 36.1% as
being in the intermediate-risk group (T2b-c) and 20.5%
being in the high-risk group (T3). Taking tumor sta-
ging, PSA measurement and the Gleason score to-
gether, clinical staging before the MRI scan resulted in
a risk group distribution for low, intermediate and
high-risk of 11.5%, 42.6% and 43.4%, respectively ac-
cording the NCCN prostate cancer guidelines. 2.5%
had suspected nodal involvement based on CT.
Table 4 Incidence of prostate cancer upstaging regarding
T stage after mpMRI
cT1–2 Tumors n Tumor upstaging (n) Percentage of
tumor upstaging
Gleason score < 7 42 19 45.2%
Gleason score 7 40 24 60%
Gleason score > 7 15 8 53%
PSA level < 10 ng/ml 44 22 50%
PSA level 10–20 ng/ml 30 16 53.3%
PSA level > 20 ng/ml 23 17 73.9%
Incidence of prostate cancer upstaging regarding T stage after mpMRI depending
on initial serum PSA level and the Gleason score in patients initially staged as
cT1–cT2 (n = 97).
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After an mpMRI scan tumor upstaging was observed in
43.4% of the patients (n = 53) relative to the original
clinical and CT-based staging. Downstaging as a result
of an mpMRI scan occurred in 12.3% (n = 15) in the
total population and in 14% (n = 8) of the 57 patients
who had received ADT before RT. Tumor stage showed
an agreement of 44.3% (95% CI: 0.36, 0.53) between CT
and clinical staging versus MRI staging (k = 0.26; 95%
CI: 0.11, 0.40). Low-risk T stage tumors (T1-2a; n = 53)
were upstaged by MRI in 67.9% of patients, whereas
intermediate-risk tumors (T2b-c; n = 44) were upstaged
in 36.4% and downstaged in 13.6%. Finally, high-risk
tumors (T3a-b; n = 25) were downstaged in 36% of pa-
tients, and in a single patient (2.5%) was upstaged to a
locally invasive tumor (T4) as a result of mpMRI
(Table 3). Depending on the initial risk factors such as
serum PSA level and the Gleason score, tumor up-
staging in T1-T2 tumors (n = 97) was observed in all
subgroups, ranging from 45.2% (low-risk Gleason
score < 6) to 73.9% (high-risk PSA level > 20 ng/ml;
Table 4 and Figure 1).Changes in risk group distribution as a result of the
mpMRI scan
Overall, mpMRI led to an upward shift of the risk
group in 25.4% patients and to a downward shift in
3.3% when compared with the initial risk group defin-
ition based on serum PSA, Gleason score as well as
the initial T stage determined by DRE, ultrasound-
guided biopsy and CT. Depending on the initial risk
group, an upward shift after mpMRI occurred in the
low-risk, intermediate-risk and high-risk group in
57.1%, 30.8% and 13.2%, respectively. A downward
shift occurred only in the initial high-risk group in
5.7%. The risk group showed an agreement rate of
71.3% (95% CI: 0.63, 0.79) between clinical staging and
MRI staging (k = 0.57; 95% CI: 0.44, 0.72). While the
percentage of patients assigned to low-risk and
intermediate-risk groups decreased, there was a sub-
stantial increase observed in the percentage of patients
assigned to the high-risk group; there was also a con-
siderable increase in the percentage of patients identi-
fied as having stage IV disease with nodal or distant
metastases. The resulting risk group distributionTable 3 Distribution of prostate cancer T stage before and af
Initial clinical staging Relative upstagin
T1–T2a ((very) low-risk) 53 (43.4%) 67.9%
T2b-c (intermediate-risk) 44 (36.1%) 36.4%
T3a-b ((very) high-risk) 25 (20.5%) 2.5%
T stage for the patients (n = 122) was attributed to specific risk groups according to
clinical staging included digital rectal examination, ultrasound-guided transrectal bibefore and after mpMRI is demonstrated in Table 5
and Figure 2.
Therapeutic implications of the tumor stage / risk group
shift as a result of the mpMRI scan
Changes in target volume definition as a result of MRI
tumor stage occurred in 30.3% of all patients (n = 37)
according to our institutional guidelines. Among the 14
patients who presented with low-risk features, 57.1%
(n = 8) were shifted to a higher risk group because of
MR-based tumor upstaging. Consequently, the CTV
was extended beyond the prostatic capsule to account
for the increased risk of microscopic ECE and/or SVI.
In the 52 patients in the intermediate-risk group, 25%
(n = 13) were shifted to the high-risk group because of
tumor upstaging, resulting likewise in an increased
periprostatic target volume margin. Finally, in the 53
patients initially classified as being in the high-risk
group 5.7% were downstaged using MRI (n = 3) with a
consequent reduction in the target volume margin and
another 5.7% had newly diagnosed SVI resulting in a
target volume extension to the whole seminal vesicles.
Additionally, nodal or distant metastases were diag-
nosed in 5.8% (n = 3) intermediate-risk patients and
13.2% high-risk patients (n = 7) resulting in a change in
treatment from locally confined RT of the prostate to
systemic therapy and/or pelvic irradiation.
Overall, the recommendations regarding the duration
of ADT were changed in 29.5% of the patients (n = 36)
after mpMRI of the prostate. Of 14 patients initially
assigned to the low-risk group, 42.9% (n = 6) were
shifted to the intermediate-risk group requiring short-ter mpMRI of the prostate
g by mpMRI Relative downstaging by mpMRI mpMRI staging
n.a. 31 (19.4%)
13.6% 49 (40.6%)
36% 46 (37.7%)
the National Comprehensive Cancer Network prostate cancer guidelines. Initial
opsy as well as an abdominal and pelvic contrast-enhanced CT scan.
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Figure 1 Distribution of T stage (A) according to CT and DRE and (B) after mpMRI of the prostate. (A) The relative extent of upstaging (grey)
und downstaging (light grey) based on mpMRI are shown compared to unchanged T stage (black) for every initial T stage.
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to the high-risk group with a consequent recommenda-
tion for long-term ADT (2–3 years). Among the inter-
mediate risk group (n = 52), 25% (n = 13) were shifted
upwards to the high-risk group resulting in a prolonged
ADT duration, and 5.8% (n = 3) had newly diagnosed
stage IV disease with an indication for palliative ADT.
Finally, in the 53 patients presenting with high-risk fea-
tures before MRI, stage IV disease was diagnosed using
MRI in 13.2% (n = 7) requiring palliative ADT. 3.8% of
the patients (n = 2) were shifted downwards to
intermediate-risk disease with an indication for short-
term ADT, and one patient (1.9%) was shifted down-
wards to the low-risk group requiring no ADT.
Risk factors for tumor stage upstaging using mpMRI
Potential risk factors which could increase the probabil-
ity of tumor upstaging as a result of the mpMRI scan of
the prostate were analyzed in patients initially staged as
T1–2 (n = 97) using univariate and multivariate logistic
regression including PSA level, the Gleason score, age
and neoadjuvant ADT. PSA level, the Gleason score and
T-stage were categorized according to the NCCN guide-
lines into low, intermediate and high-risk groups [28].
Low-risk and intermediate-risk features were analyzedTable 5 Risk group distribution before and after mpMRI of th
Clinical staging Relative upward shift b
Low-risk group 14 (11.5%) 57.1%
Intermediate-risk group 52 (42.6%) 30.8%
High-risk group 53 (43.4%) 13.2%
Nodal metastases (cN1) 3 (2.5%) 0%
Distant metastases (cM1) 0 n.a.
Risk groups for patients (n = 122) were defined according to the National Compreh
level and the Gleason score derived from prostate biopsy. n.a. = not available.separately as a relative risk factor as compared with
high-risk features. Patients presenting with intermediate-
risk PSA levels had a significantly smaller probability of
being upstaged as a result of MRI than patients in the
high-risk PSA group (p = 0.029); this probability remained
significant in multivariate analysis (p = 0.043). This trend
was also observed for lower PSA levels (<10 ng/ml),
but did not reach statistical significance in univariate
(p = 0.064) and multivariate analysis (p = 0.096). None
of the other variables investigated were significantly as-
sociated with MR-based tumor upstaging (Table 6). Of
note, downstaging of the T-stage among patients ini-
tially staged as T3a-b was not associated with any of the
variables considered in our analysis (data not shown).
Risk factors for seminal vesicle involvement detected
using mpMRI
Potential risk factors increasing the probability of newly
diagnosed seminal vesicle infiltration using mpMRI were
analyzed by means of univariate and multivariate logistic
regression in all patients (n = 122) including PSA level,
the Gleason score, initial tumor stage, age and neoadju-
vant ADT. PSA level, the Gleason score and T-stage
were divided according to the NCCN guidelines into
low, intermediate and high-risk groups. High-risk ande prostate
y mpMRI Relative downward shift by mpMRI mpMRI staging
n.a. 7 (5.7%)
0% 44 (36.1%)
5.7% 59 (48.4%)
33.3% 9 (7.4%)
n.a. 3 (2.5%)
ensive Cancer Network prostate cancer guidelines based on T stage, serum PSA
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Figure 2 Distribution of overall risk groups based on PSA, Gleason score and (A) T stage determined by CT and DRE compared to (B) T
stage assessed by mpMRI. (A) The relative extent of risk group upshift (grey) und downshift (light grey) due to mpMRI-based T stage changes
are shown for every initial risk group compared to patients without risk group shift (black).
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relative risk factor as compared with low-risk features.
PSA levels above the low-risk range were associated
with an increased risk which reached statistical signifi-
cance in univariate analysis for the intermediate-risk
PSA range (p = 0.041), but not for the high-risk PSA
range (p = 0.11). The same trend was found in multi-
variate analysis which, however, was not quite statisti-
cally significant (p = 0.058). In contrast, none of the
other factors that were evaluated appeared to play a
significant role in this investigation.
Discussion
MRI of the prostate has already been established as a
valuable tool for radiation oncologists in improving tar-
get volume delineation [35-37] and has also been investi-
gated for treatment planning [38]. It has been shown
that morphologic MRI enables a more reproducible def-
inition of the prostate gland [39-41], particularly when it
comes to the definition of the prostate apex [42,43]; it
leads to a smaller CTV volume and the sparing of more
normal tissue relative to CT-based target volume defin-
ition [44]. Consequently, in prostate cancer it has been
suggested that MRI-based treatment may reduce
treatment-associated toxicity [30].Table 6 Multivariate logistic regression analysis of potential r
OR
Low-risk PSA (<10 ng/ml) 0.37
Intermediate-risk PSA (10–20 ng/ml) 0.29
Low-risk Gleason score (<7) 0.99
Intermediate-risk Gleason score (7) 1.88
Age 1.02
ADT pre-mpMRI 1.34
Multivariate logistic regression analysis was used to demonstrate the relative proba
staged as cT1-cT2 (n = 97) depending on specific patient parameters. Patients in the
due to mpMRI than patients in the high-risk PSA group (p = 0.043). OR = Odds ratioApart from precise organ delineation, the accurate
radiological tumor staging of prostate cancer is playing
an increasingly important role in the era of IMRT [8].
Using highly-conformal RT techniques and small plan-
ning target volume margins, the detection and inclusion
of extracapsular disease and seminal vesicle infiltration
into the treatment volume is of paramount importance
in avoiding a geographic miss and consequent tumor
under-dosage [45].
MRI of the prostate can offer additional benefit in RT
planning because it is regarded as the most reliable im-
aging modality regarding the determination of the local
extension of prostate cancer, and it exhibits the highest
congruence with the “gold standard” of post-operative
pathological staging [10,11].
Surgical series have demonstrated that both the digital
rectal examination, as well as other radiological tech-
niques such as CT scans of the abdomen and transrectal
ultrasound, only exhibit low correlations with definitive
pathological staging after radical prostatectomy; indeed,
they only accurately predict the extent of the local tumor
61–70% of the time [19,20]. In contrast, morphological
T1- and T2-weighted MR imaging alone has already
shown an accuracy of 84% for the detection of extrapro-
static disease in clinically staged T2 prostate cancer [46].isk factors for T upstaging as a result of mpMRI
95% confidence interval p-value
(0.11, 1.15) 0.096
(0.08, 0.93) 0.043
(0.27, 3.65) 0.99
(0.51, 7.11) 0.34
(0.95, 1.10) 0.54
(0.55, 3.25) 0.52
bility of tumor upstaging after mpMRI of the prostate in patients initially
intermediate-risk PSA group had a significantly lower probability of upstaging
. ADT = Androgen deprivation therapy.
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into prostate cancer imaging in order to further enhance
tumor staging [14]. As a result of the early rapid en-
hancement and early washout of prostate cancer tumors,
DCE-MRI provides a means of determining tumor
extension more accurately than morphological imaging
[10], and has demonstrated an improved overall staging
accuracy of 95% in a single-institution series [17]. Inter-
estingly, this improvement in prostate cancer tumor sta-
ging due to DCE-MRI has been found to be particularly
important for less experienced readers [47]. Likewise,
recent literature reviews have confirmed that additional
DWI can detect prostate cancer tumor foci more accur-
ately than conventional anatomic imaging alone [12,48].
For these reasons, mpMRI of the prostate has been
established in our institution as a standard imaging pro-
cedure in all patients before primary RT for prostate
cancer. Although this approach is not uncommon
among RT units, it cannot at the moment be considered
as a modality with interdisciplinary consensus. Current
guidelines recommend the use of mpMRI for local sta-
ging of prostate cancer ahead of curative therapy mainly
for high-risk patients [28,31], whereas its value is ques-
tioned in patients presenting with low-risk features [49].
The purpose of the present study was therefore to
analyze retrospectively the extent of the shift in tumor
stage as a result of the use of mpMRI, and the conse-
quent impact on risk group distribution and treatment
decisions in primary RT for prostate cancer.
In our patient series, a considerable impact on pros-
tate tumor staging as a consequence of the use of
mpMRI was observed, with tumor upstaging in 43.4%
and downstaging in 12.3% of patients. These findings
are consistent with the findings from a previously pub-
lished series of 199 patients with localized prostate can-
cer; in this series morphological MRI scans of the
prostate, without DCE imaging or DWI, led to tumor
upstaging in 52% and to tumor downstaging in 3% of
patients before RT [25].
Although our study showed a trend towards a signifi-
cantly lower probability of MRI-based tumor upstaging
in patients with an intermediate or low-risk PSA level,
there was no subgroup identifiable where it appeared
reasonable to omit mpMRI before RT. Even in the low-
risk subgroups (Gleason score < 7; PSA level < 10 ng/ml),
a substantial upstaging of 45–50% could be observed.
However, taking all of the established risk factors, such
as the Gleason score, PSA level and tumor stage to-
gether, mpMRI of the prostate only led to a change in
risk group in 25.4% of the patients in our series. This
might be explained by the fact that patients with a lo-
cally advanced tumor stage detected by MRI may often
present with other adverse features which had already
been assessed before MRI.Tumor stage shift and change in risk group taken to-
gether resulted in a change in the RT dose and target
volume, as well as in the recommendations for add-
itional ADT in 30% of patients. These findings are in
concordance with recent data from a study by Chang
et al. [24] who reported a significant upstaging of 29%
before primary RT for prostate cancer in a comparable
patient series, using morphological MRIs without multi-
parametric dynamic sequences. Interestingly, Clure et al.
reported a similar extent of treatment adaptation of 27%
as a result of MRI staging in a series of 104 patients
who underwent robotic-assisted laparoscopic prosta-
tectomy [50]. Similarly, Hricak et al. reported a change
in surgical plan based on MRI scans in 39% of patients
who underwent radical prostatectomy for localized
prostate cancer [51].
Whereas it seems to be legitimate to increase treatment
intensity for patients with mpMRI based upstaging,
caution should be exerted for treatment de-intensification
in cases where mpMRI led to downstaging: in our series, a
considerable number of downstaging was found in
patients who received ADT before RT. It is, however,
mainly not determinable whether MR-based downstaging
occured due to previous diagnostic inaccuracy of the pre-
MRI staging or if it was an ADT effect. If the latter can’t
be definitely ruled out, downstaging should not subse-
quently lead to de-intensification of radiotherapy. In order
to avoid this uncertainty of ADT interference, mpMRI
should be conducted as part of the initial staging proced-
ure before start of any neoadjuvant treatment.
Our study had several limitations. First, all data were
reviewed retrospectively and staging information was
obtained from patient histories. In addition, the report-
ing radiologists had not been blinded to previously ob-
tained clinical staging. However, these circumstances
may represent the daily practice in a major cancer center
more accurately than would be the case in a dedicated
prospective trial. Second, clinical and MRI staging were
not correlated to oncological outcome as has been
reported in other studies [25,52]; this was because the
follow-up time was limited as we evaluated a very recent
patient series. The main focus of our study was on the
impact of MRI staging on treatment decisions, not on
its predictive value. mpMRI sequences were not
reported separately from morphological MRI, so their
additional value for treatment decisions could not be
independently assessed. Additionally, in contrast to
studies regarding the surgical treatment of prostate
cancer, MRI staging could not be validated using defini-
tive pathological staging. Finally, the impact of MRI on
target volume delineation and treatment volume rela-
tive to CT-based planning was not analyzed in the
current study, because it has been investigated exten-
sively by others [29,30,53].
Panje et al. Radiation Oncology  (2015) 10:47 Page 8 of 9Conclusions
The use of mpMRI in patients admitted for primary RT
for prostate cancer resulted in a substantial shift in
tumor stage in > 50%, with consequent treatment adapta-
tions in nearly one third of the patients. In our single
center series, we could not identify any subgroup of pa-
tients where mpMRI did not lead to considerable up-
staging. In conclusion, our findings suggest that patients
from all risk groups may benefit from mpMRI of the pros-
tate regarding the choice of the optimal risk-adapted RT.
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